What Is Eppe (Efpeglenatide)? South Korea’s New GLP-1 Weight Loss Drug Explained
The global GLP-1 revolution in obesity medicine, driven by Wegovy, Mounjaro, and their accelerating successors, has largely been a story written in the United States, Denmark, and the European Union. That story now has a new chapter, and it begins in Seoul.
In October 2026, Hanmi Pharmaceutical became the first Korean company to win regulatory approval for a domestically developed GLP-1 receptor agonist for obesity. The drug is called Eppe, its active ingredient is efpeglenatide, and its approval marks a milestone not just for Hanmi, but for South Korea's broader ambitions in biopharmaceutical independence.
For patients, physicians, and health professionals watching the GLP-1 landscape evolve, Eppe raises real and practical questions. How does it work? How effective is it? And how does it sit alongside the global market leaders it now competes against?
This article explains what the science shows, clearly and without overstatement, and what Eppe's approval means for the broader direction of obesity medicine.
This article is for informational and educational purposes only and does not constitute medical advice. Eppe is currently approved only in South Korea. Patients considering any GLP-1 therapy should consult a licensed physician or obesity medicine specialist. Always discuss options based on what is actually available in your jurisdiction.
The Short Answer
Eppe is the brand name for efpeglenatide, a once-weekly GLP-1 receptor agonist developed by Hanmi Pharmaceutical and approved by South Korea's Ministry of Food and Drug Safety in October 2026. It is the first GLP-1 obesity drug developed entirely in Korea and the country's 45th homegrown new drug.
Clinical trial data shows an average weight loss of approximately 9 to 10 percent of body weight over 40 weeks, below the 15 percent typical of Wegovy (semaglutide) and the 22 percent reported for Mounjaro (tirzepatide). What Eppe offers in return is a smoother side effect profile (through Hanmi's proprietary flat pharmacokinetic delivery platform), a locally anchored supply chain, Phase 3 data specific to the Korean obesity phenotype, and cardiovascular and renal protective data from a large-scale global CVOT.
As of late 2026, Eppe is approved only in South Korea. It is not available in the Philippines or other markets. For Filipino patients, the clinically relevant options remain semaglutide and tirzepatide, delivered through physician-supervised programmes such as SHAPE at Jan Medical Group. Eppe is a meaningful development worth watching, but it is not yet a treatment pathway accessible outside Korea.
What Efpeglenatide Is
Efpeglenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone naturally secreted by cells in the gastrointestinal tract in response to food intake. It stimulates insulin secretion, suppresses glucagon release, signals satiety to the brain, and slows gastric emptying. All of these effects collectively reduce appetite and support weight loss.
What makes efpeglenatide structurally distinct is how it was engineered. The drug was developed using Hanmi's LAPSCOVERY (Long Acting Protein/Peptide Discovery) platform, in which the GLP-1 therapeutic agent is conjugated with a human immunoglobulin G Fc fragment via a linking molecule. This conjugation extends the molecule's half-life significantly, allowing for once-weekly dosing rather than the daily alternatives of earlier-generation GLP-1 therapies such as liraglutide (Saxenda).
The clinically relevant result is a flatter, more stable pharmacokinetic profile than conventional GLP-1 drugs. This smoothness of release matters for tolerability, which in turn matters for adherence.
Eppe (Efpeglenatide): Korea's First Homegrown GLP-1 Obesity Drug
Regulatory Approval and Clinical Significance
Hanmi Pharmaceutical will launch efpeglenatide, Korea's first GLP-1 obesity drug, following approval from the Ministry of Food and Drug Safety. Eppe is the 45th homegrown new drug approved in Korea, a designation that reflects years of independent clinical development.
That designation carries weight beyond ceremony. The programme that produced Eppe survived an early setback: a foreign pharmaceutical partner previously returned the rights to the compound. Hanmi chose to redevelop it independently, repositioning it specifically for the Korean obesity phenotype.
The Ministry of Food and Drug Safety granted manufacturing and marketing approval for Hanmi Pharm's Eppe Auto-Injector (efpeglenatide) in five dosage strengths: 2, 4, 6, 8, and 10 milligrams. The drug is a subcutaneous injection indicated for chronic weight management in adults with obesity (BMI of 30 kg/m² or above) as well as overweight adults (BMI of 27 to below 30 kg/m²) who have at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease.
It is worth noting that Korean clinical guidelines define obesity at a BMI of 25 kg/m² or above, a lower threshold than the Western standard of 30 kg/m². This reflects the metabolic risk profile of East Asian body compositions, where insulin resistance and visceral fat accumulation occur at lower absolute body weights. Hanmi designed its Phase 3 trial around Korean patients, making Eppe one of the first GLP-1 drugs with Phase 3 efficacy data specific to this population, a point that has direct relevance for Filipino and Southeast Asian patients whose metabolic physiology is closer to the Korean profile than to the Western one.
How the LAPSCOVERY Platform Reduces Side Effects
One of the persistent barriers to GLP-1 therapy adherence is gastrointestinal intolerance, particularly nausea and vomiting during dose escalation. Eppe addresses this through two mechanisms working in combination.
First, the LAPSCOVERY platform achieves a flat pharmacokinetic profile. The drug is absorbed and released gradually, rather than producing the peaks and troughs associated with conventional GLP-1 delivery. This smoother absorption pattern reduces the intensity of the appetite-signalling effects at any single moment, which in turn reduces the gastrointestinal burden.
Second, Eppe uses a stepwise dose-escalation regimen with intervals of two and then four weeks, substantially reducing gastrointestinal side effects such as nausea and vomiting at each step up.
This combination matters in practice. Many patients discontinue GLP-1 therapy not due to lack of efficacy, but because nausea during the titration phase becomes intolerable. A drug that delivers comparable appetite suppression with a smoother onset profile has a meaningful clinical advantage in real-world adherence, even when peak efficacy numbers are lower than competing agents.
What the Phase 3 Clinical Trial Data Shows
Efficacy: Weight Loss Outcomes
After 40 weeks of treatment, patients receiving efpeglenatide lost an average of 9.02 percent of their initial body weight, compared to 0.89 percent for the placebo group. In the efpeglenatide group, 75.1 percent of patients lost at least 5 percent of their body weight, compared to 13.5 percent in the placebo group.
Interim results previously reported by Hanmi showed a slightly higher figure: Eppe reduced body weight by an average of 9.75 percent over 40 weeks in a Phase 3 trial of 448 Korean patients. Additionally, 49.46 percent achieved weight loss of at least 10 percent, while 19.86 percent lost at least 15 percent.
The full clinical trial lasted 64 weeks, with the weight loss observed through week 40 tending to persist through week 64. The final average weight loss rate at week 64 has not been publicly disclosed.
How It Compares to Wegovy(Semaglutide) and Mounjaro(Tirzepatide)
Context matters here. Eppe's Korean Phase 3 trial reported average weight loss of approximately 9.75 percent over 40 weeks, below the 15 to 20 percent reductions reported in studies of imported treatments. This gap is real and should not be
minimised.
Several important caveats apply.
Eppe has not been tested head to head against Wegovy or Mounjaro. Cross-trial comparisons are methodologically unreliable, since they involve different patient populations, baseline BMIs, trial designs, and study durations.
Eppe's Korean trial enrolled patients reflecting the Korean obesity phenotype, a population that may respond differently to GLP-1 therapy than the predominantly Western populations in Wegovy and Mounjaro trials. This matters for cross-regional interpretation.
And Eppe's side effect profile may support longer, more consistent treatment adherence, which influences real-world outcomes more than peak trial efficacy figures. The best medication is the one patients actually stay on.
Cardiovascular and Renal Data
Additional clinical strengths include a demonstrated reduction in major cardiovascular events and renal protective effects, confirmed through a large-scale global Phase 3 cardiovascular outcomes trial (CVOT) involving approximately 4,000 participants.
Cardiovascular outcome data is increasingly central to how GLP-1 drugs are evaluated, both for clinical guidelines and for insurance reimbursement decisions. The fact that efpeglenatide has this data from a large CVOT is a meaningful differentiator in an era where regulators increasingly want to see outcomes beyond weight reduction alone.
Market Context: Eppe vs. the Global GLP-1 Giants
Eppe enters a Korean GLP-1 market of approximately 2 trillion won currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Mounjaro. Hanmi manufactures the drug at its own biopharma plant in Pyeongtaek, from active pharmaceutical ingredient through to finished product, giving it a stable in-country supply chain.
The company plans to price Eppe competitively to lower the initial barrier to entry and maximise its import-substitution effect. This local manufacturing model is strategically significant. The global GLP-1 drug shortage, driven by overwhelming worldwide demand for Wegovy and Ozempic, has affected Korean patients too. A domestically produced alternative with a stable supply chain addresses a real access gap.
Hanmi has also announced plans for a digital combination drug that integrates efpeglenatide with a personalised digital therapeutic component, a first-of-its-kind approach in Korea that would use patient-recorded food and exercise data to inform dosing and weight-loss targets. This is still in development.
What Eppe's Approval Means for the Philippines and Southeast Asia
For Filipino patients, the direct practical answer is that Eppe is not currently available locally. As of late 2026, Hanmi Pharmaceutical has not announced regulatory submissions to the US FDA, the European Medicines Agency, or health authorities in Southeast Asia, including the Philippine FDA. International availability will depend on future regulatory submissions and approvals.
The indirect significance is more interesting. Eppe's development validates several principles with clinical relevance beyond Korea.
Asian-specific Phase 3 data is a meaningful advance. Filipino, Korean, and other Southeast Asian populations develop metabolic dysfunction at lower BMI thresholds than Western reference groups. Clinical data generated in Asian populations is more directly applicable to Filipino patients than data from US or European trials. Eppe's Korean Phase 3 trial is one of the few GLP-1 studies conducted at this population scale.
Tolerability is a clinically legitimate differentiator. The obesity medicine conversation has largely been driven by peak weight loss figures. Eppe's positioning around smoother pharmacokinetics and better adherence is a reminder that the best outcome is not always produced by the strongest molecule, but by the one patients can consistently sustain.
Local manufacturing of GLP-1 medications is now viable. Hanmi's end-to-end in-house production model, combined with its intention to price competitively, signals that the GLP-1 class is moving from a scarce, premium-priced category toward broader accessibility. This trajectory, once it reaches regional distribution, will matter for Filipino patients.
For patients in the Philippines considering medical weight management today, the clinically available options remain semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), delivered through physician-supervised programmes. Eppe is a development to understand, not a treatment to pursue. Both medications are available through the SHAPE programme at Jan Medical Group, with SHAPE Sustain using semaglutide and SHAPE Ultra using tirzepatide, under physician supervision at both the BGC and Quezon City branches.
Frequently Asked Questions
Q: What is Eppe and who makes it?
Eppe is the brand name for efpeglenatide, a once-weekly injectable GLP-1 receptor agonist developed entirely by South Korean biopharmaceutical company Hanmi Pharmaceutical. It received regulatory approval from South Korea's Ministry of Food and Drug Safety in October 2026, making it the first homegrown GLP-1 obesity drug in Korea and the country's 45th domestically developed new drug.
Q: How much weight can you lose with Eppe (efpeglenatide)?
In Hanmi's Korean Phase 3 clinical trial, patients taking efpeglenatide lost an average of approximately 9.02 to 9.75 percent of their initial body weight over 40 weeks, compared to less than 1 percent for placebo. Around 75 percent of patients achieved at least 5 percent weight loss, approximately 49 percent achieved 10 percent or more, and roughly 20 percent achieved 15 percent or more.
Q: Is Eppe better than Wegovy or Mounjaro?
No head-to-head trials have directly compared Eppe against Wegovy or Mounjaro. Based on placebo-controlled trial data, Eppe produces lower average weight loss (approximately 9 to 10 percent) than Wegovy (approximately 15 percent) or Mounjaro (approximately 20 to 22 percent). However, Eppe may offer advantages in terms of tolerability, side effect profile, supply availability within Korea, and population-specific trial data. These comparisons must be interpreted with care, since the trial populations and designs differ significantly.
Q: What are the side effects of efpeglenatide?
Like other GLP-1 receptor agonists, efpeglenatide can cause gastrointestinal side effects including nausea and vomiting, particularly during dose escalation. However, Hanmi reports that the LAPSCOVERY platform's flat pharmacokinetic profile and stepwise dose titration regimen substantially reduce these effects compared to conventional GLP-1 drugs. Early clinical data also noted a slight increase in heart rate, consistent with the known profile of the GLP-1 drug class.
Q: Is Eppe available outside of South Korea?
As of late 2026, Eppe has only received regulatory approval in South Korea. Hanmi Pharmaceutical has not announced regulatory submissions to the US FDA, the European Medicines Agency, or health authorities in Southeast Asia, including the Philippine FDA. International availability will depend on future regulatory submissions and approvals.
Q: Who is Eppe indicated for?
Eppe is approved for adults with obesity (BMI of 30 kg/m² or above without diabetes) and for overweight adults (BMI of 27 to below 30 kg/m²) who have at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease. It is used alongside diet modification and exercise, not as a standalone intervention.
Q: What GLP-1 options are available to Filipino patients today?
For patients in the Philippines, the clinically available options are semaglutide (sold as Wegovy for weight management and Ozempic for diabetes) and tirzepatide (Mounjaro for diabetes and Zepbound for weight management). Both are available through licensed pharmaceutical channels and through physician-supervised programmes such as SHAPE at Jan Medical Group, with branches at BGC (Park Triangle Mall, Taguig) and Quezon City (Bengar Building, Del Monte Avenue, Brgy. Manresa).
Why This Approval Matters
The approval of Eppe is more than a commercial milestone for Hanmi Pharmaceutical. It is a proof point for Asian pharmaceutical ambition, that a domestic company can develop, trial, manufacture, and bring to market a drug in one of the most competitive therapeutic categories in global medicine today.
Does Eppe produce the same magnitude of weight loss as Wegovy or Mounjaro? Based on the current data, no. But the GLP-1 field has never been purely about maximum weight loss numbers. It is about finding the right drug for the right patient, one that balances efficacy with tolerability, that can be consistently accessed and afforded, and that is supported by meaningful cardiovascular outcome data.
For Korean patients in particular, a population underserved by Western-centred trial designs and affected by global supply shortages of imported GLP-1 drugs, Eppe represents a genuinely meaningful clinical option. For Filipino patients, Eppe is not yet an accessible treatment, but its approval signals a direction the obesity medicine field is moving in: Asian-specific data, better tolerability, and broader accessibility.
What comes next will be telling. Pricing disclosure, real-world adherence data, the 64-week efficacy figures, and any international regulatory applications will shape how Eppe fits into the broader global obesity treatment landscape. For now, it is a credible, locally anchored, clinically meaningful addition to the GLP-1 class, and one worth watching closely as the field continues to evolve.
For patients in the Philippines considering medical weight management now, the right starting point remains a physician consultation that evaluates your health profile and matches you to the medication clinically appropriate and currently available for your care.
Comments